Advertisement
MO BIO
MO BIO

Pfizer embraces stem cells

Big pharma's interest in linkurl:stem cell research;http://www.the-scientist.com/blog/display/54900/ is picking up speed. Pharmaceutical giant Pfizer is expanding its research into the technology and plans to open a second regenerative medicine unit in Cambridge, UK, this November, Reuters linkurl:reported;http://www.reuters.com/article/reutersEdge/idUSTRE48MBY020080923?sp=true yesterday. Pfizer isn't the only one. In July, GlaxoSmithKline entered a linkurl:5-year, $25 million collaboration;ht

By | September 24, 2008

Big pharma's interest in linkurl:stem cell research;http://www.the-scientist.com/blog/display/54900/ is picking up speed. Pharmaceutical giant Pfizer is expanding its research into the technology and plans to open a second regenerative medicine unit in Cambridge, UK, this November, Reuters linkurl:reported;http://www.reuters.com/article/reutersEdge/idUSTRE48MBY020080923?sp=true yesterday. Pfizer isn't the only one. In July, GlaxoSmithKline entered a linkurl:5-year, $25 million collaboration;http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10089.htm with the Harvard Stem Cell Institute. In the spring, Pfizer opened a regenerative medicine unit in Cambridge, Massachusetts, focusing on stem cells for cardiac disorders and cancer, according to the linkurl:company's Web site.;http://www.pfizer-regenerativemedicine.com/locations/index.php The new UK site will eventually house 60 scientists and research will focus on age-related and degenerative and nervous system disorders. While Pfizer's stem cell research policy does not rule out the use of embryonic stem cells, the company is also extremely interested in induced pluripotent stem (iPS) cells, John McNeish, head of the Massachusetts operation, told Reuters at the World Stem Cell Summit, held this week in Madison, Wisconsin. In June, Pfizer also entered a linkurl:$3 million partnership;http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&newsId=20080623005677&newsLang=en with EyeCyte, Inc., a California company whose technology uses blood and bone marrow progenitor cells to treat retinal diseases.
Advertisement
Advertisement

Popular Now

  1. The Mycobiome
    Features The Mycobiome

    The largely overlooked resident fungal community plays a critical role in human health and disease.

  2. Antibody Alternatives
    Features Antibody Alternatives

    Nucleic acid aptamers and protein scaffolds could change the way researchers study biological processes and treat disease.

  3. Circadian Clock and Aging
    Daily News Circadian Clock and Aging

    Whether a critical circadian clock gene is deleted before or after birth impacts the observed aging-related effects in mice.

  4. Holding Their Ground
    Features Holding Their Ground

    To protect the global food supply, scientists want to understand—and enhance—plants’ natural resistance to pathogens.

Advertisement
PDA
PDA
Advertisement
Life Technologies